Antitumor activity of arsenic trioxide on retinoblastoma: Cell differentiation and apoptosis depending on arsenic trioxide concentration

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 4, 2009, Pages 1819-1823

  Kim, Jin Hun ^a,b   Kim, Jin Hyoung ^a,b   Yu, Young Suk ^a,b   Kim, Dong Hun ^c   Kim, Chong Jai ^a   Kim, Kyu Won ^d  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Soonchunhyang University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RETINA TUMOR; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; HYDROGEN PEROXIDE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXIDES; PHOSPHORYLATION; RETINAL NEOPLASMS; RETINOBLASTOMA; TUMOR CELLS, CULTURED;

EID: 64049116808     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2623     Document Type: Article

References (22)

1. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24(6):828-848.
2. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist. 2007;12(10):1237-1246.
3. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent externalbeam irradiation and enucleation in lowstage intraocular retinoblastoma. J Clin Oncol. 2000;18(5):2881-2887.
4. Kim JH, Yu YS, Khwarg SI, Choi HS, Shin HY, Ahn HS. Clinical result of prolonged primary chemotherapy in retinoblastoma patients. Korean J Ophthalmol. 2003;17(1):35-43.
5. Shields CL, Shields JA, De Potter P. New treatment modalities for retinoblastoma. Curr Opin Ophthalmol. 1996;7(3):20-26.
6. Nishimura S, Sato T, Ueda H, Ueda K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol. 2001;19(21):4182-4183.
7. Yoon CY, Shim YJ, Kim EH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer. 2007; 120:897-905.
8. Kim JH, Kim JH, Yu YS, Kim DH, Min BH, Kim KW. Antitumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep. 2007;18(6):1373-1377.
9. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, followup, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94(10):3315-3324.
10. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62(14):3893-3903.
11. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 2001;6(suppl 2):22-28.
12. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dosedependent dual effects on APL cells. Blood. 1997; 89(9):3345-3353.
13. Sordet O, Rébé C, Leroy I, et al. Mitochondriatargeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood. 2001;97(12): 3931-3940.
14. Jung HS, Kim HS, Lee MJ, et al. Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro. FEBS Lett. 2006;580(20):4969-4975.
15. Becker LE, Hinton D. Primitive neuroectodermal tumors of the central nervous system. Hum Pathol. 1983;14(6):538-550.
16. Dyer MA. Mouse models of childhood cancer of the nervous system. J Clin Pathol. 2004;57(6):561-576.
17. Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ, Kim KW. Establishment and characterization of a novel, spontaneously immortalized retinoblastoma cell line with adherent growth. Int J Oncol. 2007; 31(3):585-592.
18. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1(10):851-860.
19. McCafferty-Grad J, Bahlis NJ, Krett N, et al. Arsenic trioxide uses caspasedependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther. 2003;2(11):1155-1164.
20. Ora I, Bondesson L, Jönsson C, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun. 2002;277(1):179-185.
21. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol. 1998;177(2):324-333.
22. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410(6828):549-554.